

66-

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 295/08, 295/22, C07C 233/41, A61K 31/535		A1	(11) International Publication Number: WO 99/21846
			(43) International Publication Date: 6 May 1999 (06.05.99)
(21) International Application Number: PCT/US98/22765		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 27 October 1998 (27.10.98)		<p>Published</p> <p><i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>AC</p>	
(30) Priority Data: 60/063,669 28 October 1997 (28.10.97) US			
(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL CORP. [US/US]; U.S. Route 202, Raritan, NJ 08869-0602 (US).			
(72) Inventors: CHEN, Robert, II.; 39 Beverly Drive, Belle Mead, NJ 08502 (US). XIANG, Min; 29 Forest Avenue, Bridgewater, NJ 08807 (US). MOORE, John, B., Jr.; 19 Goldfinch Lane, Neshanic Station, NJ 08853 (US). BEAVERS, Mary, Pat; 518 Waterford Court, New Hope, PA 18938 (US).			
(74) Agents: CIAMPORCERO, Audley et al.; Johnson and John- son, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 7003 (US).			

(54) Title: CYCLOPENTENE DERIVATIVES USEFUL AS ANTAGONISTS OF THE MOTILIN RECEPTOR

(57) Abstract

The compounds of formula (I) are useful in treating gastrointestinal disorders associated with antagonizing the motilin receptor disorders. The compounds compete with erythromycin and motilin for the motilin receptor. In addition the compounds are antagonists of the contractile smooth muscle response to these ligands.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CYCLOPENTENE DERIVATIVES USEFUL AS ANTAGONISTS OF THE MOTILIN RECEPTOR

CROSS REFERENCE TO RELATED APPLICATION

5 This application claims the priority of provisional application Serial Number 60/063,669, filed October 28, 1997.

FIELD OF THE INVENTION

This invention relates to a series of novel cyclopentene derivatives, pharmaceutical compositions containing them and intermediates used in their
10 manufacture. The compounds of the invention are useful as non-peptidyl antagonists of the motilin receptor. In addition, the compounds display efficacy and potency which are comparable to known motilin and erythromycin antagonists.

BACKGROUND

15 In mammals, the digestion of nutrients and the elimination of waste is controlled by the gastrointestinal system. This system is, to say the least, complicated. There are a number of natural peptides, ligands, enzymes, and receptors which play a vital role in this system and are potential targets for drug discovery. Modifying the production of, or responses to these
20 endogenous substances can have an effect upon the physiological responses such as diarrhea, nausea, and abdominal cramping. One example of an endogenous substance which affects the gastrointestinal system is motilin.

Motilin is a peptide of 22 amino acids which is produced in the gastrointestinal system of number of species. Although the sequence of the
25 peptide varies from species to species, there are a great deal of similarities. For example, human motilin and porcine motilin are identical; while motilin isolated from the dog and the rabbit differ by five and four amino acids respectively. Motilin induces smooth muscle contractions in the stomach tissue of dogs, rabbits, and humans as well as in the colon of rabbits. Apart
30 from local gastrointestinal intestinal tissues, motilin and its receptors have been found in other areas. For example motilin has been found in circulating plasma, where a rise in the concentration of motilin has been associated with

gastric effects which occur during fasting in dogs and humans. Itoh, Z. et al. *Scand. J. Gastroenterol.* 11:93-110, (1976); Vantrappen, G. et al. *Dig. Dis Sci* 24, 497-500 (1979). In addition, when motilin was intravenously administered to humans it was found to increase gastric emptying and gut hormone
5 release. Christofides, N.D. et al. *Gastroenterology* 76:903-907, 1979.

Aside from motilin itself, there are other substances which are agonists of the motilin receptor and which elicit gastrointestinal emptying. One of those agents is the antibiotic erythromycin. Even though erythromycin is a useful drug, a great number of patients are affected by the drug's
10 gastrointestinal side effects. Studies have shown that erythromycin elicits biological responses that are comparable to motilin itself and therefore may be useful in the treatment of diseases such as chronic idiopathic intestinal pseudo-obstruction and gastroparesis. Weber, F. et al., *The American Journal of Gastroenterology*, 88:4, 485-90 (1993).


15 Although motilin and erythromycin are agonists of the motilin receptor, there is a need for antagonists of this receptor as well. The nausea, abdominal cramping, and diarrhea which are associated with motilin agonists are not always welcome physiological events. The increased gut motility induced by motilin has been implicated in diseases such as Irritable Bowel
20 Syndrome and esophageal reflux. Therefore researchers have been searching for motilin antagonists.

One such antagonist is OHM-11526. This is a peptide derived from porcine motilin which competes with both motilin and erythromycin for the motilin receptor in a number of species, including rabbits and humans. In
25 addition, this peptide is an antagonist of the contractile smooth muscle response to both erythromycin and motilin in an *in vitro* rabbit model. Depoortere, I. et al., *European Journal of Pharmacology*, 286, 241-47, (1995). Although this substance is potent in that model (IC_{50} 1.0 nm) it is a peptide and as such offers little hope as an oral drug since it is susceptible to
30 the enzymes of the digestive tract. Zen Itoh, *Motilin*, xvi (1990). Therefore it is desirable to find other agents which are not peptides as potential motilin antagonists. The compounds of this invention are such agents.

The compounds of this invention are non-peptidyl motilin antagonists with potencies and activities comparable to known peptidyl motilin antagonists. These compounds compete with motilin and erythromycin for the motilin receptor site in vitro. In addition, these compounds suppress smooth muscle contractions induced by motilin and erythromycin with activities and potencies comparable to OHM 11526 in an in vitro model.

SUMMARY OF THE INVENTION

The present invention is directed to compounds of Formula I



wherein

- 15 R_1 is hydrogen, C_{1-5} alkyl, substituted C_{1-5} alkyl (where the alkyl substituents are one or more halogens), amino C_{1-5} alkyl, C_{1-5} alkylamino C_{1-5} alkyl; di- C_{1-5} alkylamino C_{1-5} alkyl, $R_a R_b N-C_{1-5}$ alkyl (where the R_a and R_b are independently selected from hydrogen and C_{1-5} alkyl, or are taken together to form a morpholine, piperazine, piperidine, or N-substituted piperidine where the N- substituent is
- 20 C_{1-5} alkyl or phenyl C_{1-5} alkyl), C_{1-5} alkylcarbonyl, C_{1-5} alkoxycarbonyl, aminocarbonyl, C_{1-9} alkylaminocarbonyl, cyclo C_{3-9} alkylaminocarbonyl, pyridinylcarbonyl, substituted pyridinylcarbonyl (where the pyridinyl substituents are selected from the group consisting of one or more
- 25 halogens and C_{1-5} alkyl), thiophenecarbonyl, substituted thiophenecarbonyl (where the thiophene substituents are selected from the group consisting of one or more halogens and C_{1-5} alkyl), phenyl, phenyl C_{1-5} alkyl, phenoxycarbonyl, phenylcarbonyl, diphenylmethylcarbonyl, phenylaminocarbonyl, phenylthiocarbonyl,

- phenylaminothiocarbonyl, substituted phenyl, substituted phenylC₁₋₅alkyl, substituted phenoxycarbonyl, substituted phenylcarbonyl, substituted phenylaminocarbonyl, substituted diphenylmethylcarbonyl, substituted phenylthiocarbonyl, and substituted phenylaminothiocarbonyl (where the phenyl substituents are selected from the group consisting of one or more of halogen, C₁₋₅alkyl, trihalomethyl, C₁₋₅alkoxy, amino, nitrile, nitro, C₁₋₅alkylamino, di-C₁₋₅alkylamino, if there are more than one substituents they may be taken together with the phenyl ring to form a fused bicyclic 7-10 membered heterocyclic ring having one to two heteroatoms selected from oxygen, sulfur or nitrogen or the substituents may be taken together to form a fused bicyclic 7-10 membered aromatic ring;
- R₂ is hydrogen, C₁₋₅alkyl, C₁₋₅alkoxy, phenyl, substituted phenyl (where the phenyl substituents are selected from one or more of the group consisting of halogen and C₁₋₅alkyl), phenylC₁₋₅alkyl, substituted phenylC₁₋₅alkyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C₁₋₅alkyl, C₁₋₅alkoxy, halo and di-C₁₋₅alkylamino)
- R₃ is hydrogen, C₁₋₅alkylcarbonyl, substituted C₁₋₅alkylcarbonyl (where the alkyl substituents are selected from one or more halogens), phenylcarbonyl, and substituted phenylcarbonyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C₁₋₅alkyl, C₁₋₅alkoxy, amino, C₁₋₅alkylamino, and di-C₁₋₅alkylamino)
- R₄ is hydrogen, C₁₋₅alkylcarbonyl, substituted C₁₋₅alkylcarbonyl (where the alkyl substituents are selected from one or more halogens), phenylcarbonyl, and substituted phenylcarbonyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C₁₋₅alkyl, C₁₋₅alkoxy, amino, C₁₋₅alkylamino, and di-C₁₋₅alkylamino)
- n is 0-3;

m is 1-5

R₅ is $X-(CH_2)_q-(A)_t$

where:

q is 0-2;

t is 0-1;

X is oxygen, CH₂, sulfur, or NR_c where

R_c is hydrogen, C₁₋₅alkyl, morpholinoC₁₋₅alkyl,

piperidinylC₁₋₅alkyl, N-phenylmethylpiperidinyl or

piperazinylC₁₋₅alkyl,

with the proviso that if q and t are 0, then X is hydroxy, thiol, or amino,

A is C₁₋₅alkoxycarbonyl, phenylcarbonyl, or R₇R₈N-

where R₇ is independently selected from hydrogen, C₁₋₅alkyl,

cycloC₃₋₉alkyl, or R₇ is taken together with R₈ to form a

5 or 6 membered heterocyclic ring with one or more

heteroatoms selected from the group consisting of

oxygen, nitrogen or sulfur and N-oxides thereof;

R₈ is independently selected from hydrogen, C₁₋₅alkyl,

cycloC₃₋₉alkyl or taken together with R₇ to form a 5 or

6 membered heterocyclic ring with one or more

heteroatoms selected from the group consisting of

oxygen, nitrogen or sulfur, and N-oxides thereof;

R₆ is hydrogen, halogen, C₁₋₅alkoxy, C₁₋₅alkylamino, or di-C₁₋₅alkylamino or pharmaceutically acceptable salts thereof.

The compounds of formula I are useful in treating gastrointestinal disorders associated with the motilin receptor. The compounds compete with erythromycin and motilin for the motilin receptor. In addition, the compounds are antagonists of the contractile smooth muscle response to those ligands.

The present invention also comprises pharmaceutical compositions containing one or more of the compounds of formula I as well as methods for the treatment of disorders related to the gastrointestinal system which are associated with the motilin receptor. Such diseases include Irritable Bowel

Syndrome, esophageal reflux, and the gastrointestinal side effects of erythromycin.

DETAILED DESCRIPTION OF THE INVENTION

5

The terms used in describing the invention are commonly used and known to those skilled in the art. However, the terms that could have other meanings are defined. "Independently" means that when there are more than one substituent, the substituents may be different. The term "alkyl" refers to
10 straight, cyclic and branched-chain alkyl groups and "alkoxy" refers O-alkyl where alkyl is as defined supra. The symbol "Ph" refers to phenyl, the term "fused bicyclic aromatic" includes fused aromatic rings such as naphthyl and the like. The term "fused bicyclic heterocycle" includes benzodioxoles and the like.

15

Since the compounds of the invention have a chiral center, some of the compounds are isolated as enantiomers. In those cases the determination of absolute stereochemistry is pending.

When compounds contain a basic moiety, acid addition salts may be prepared and may be chosen from hydrochloric, hydrobromic, hydroiodic,
20 perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, 2-phenoxybenzoic, 2-acetoxybenzoic, or saccharin, and the like. Such salts can be made by reacting the free base of
25 compounds of formula I with the acid and isolating the salt.

The compounds of the invention may be prepared by the following schemes, where some schemes produce more than one embodiment of the invention. In those cases, the choice of scheme is a matter of discretion which is within the capabilities of those skilled in the art.

30

A synthesis of the compounds of the invention is depicted in Scheme 1. Essentially this scheme assembles two halves of the molecule and couples them. For one half, 3-ethoxy-2-cyclohexen-1-one, 1a, is the starting


material. 1a is treated with a Grignard reagent, 1b, such as 4-fluorobenzyl magnesium bromide at room temperature under an inert atmosphere, using ether as a solvent to give the α,β -unsaturated ketone derivative 1c. Treatment of 1c with a reducing agent such as LAH at 0 °C to room
5 temperature over 16 h gives the alcohol, 1d. This alcohol is treated with a strong base such as NaH and trichloroacetonitrile from 0 °C to room temperature for 16 h to give the amide 1e. This six membered ring amide is sequentially treated with ozone at -78 °C, dimethylsulfide, and a catalytic amount of acid such as toluene sulfonic acid. Once addition is complete, the
10 mixture is allowed to warm to room temperature over 24-64 h to give the five membered ring aldehyde 1f, as a racemic mixture.

To assemble the other half, an aromatic alcohol 1g, such as 3-hydroxyaniline is treated with a mild base, such as K_2CO_3 , in a suitable solvent such as EtOH at 60 °C over 4-6 h. This mixture is subsequently
15 treated with a halide derivative 1h, such as 3-chloropropylmorpholine at room temperature to give the amine 1i. This amine is treated with the aldehyde 1f and $NaCNBH_3$ in MeOH at room temperature over 30 min to give a compound of the invention, 1j as a racemic mixture.

If pure enantiomers are desired, they may be obtained in any of three
20 stages of the synthesis. The alcohol 1d, the aldehyde 1f, and the product 1j may all be separated via HPLC using chiral columns or methods known of those skilled in the art. With respect to all three compounds, they may be further manipulated to give other compounds of the invention without sacrificing their enantiomeric purity.


25 This scheme may be used to produce other compounds of the invention. For example, to produce compounds where X is sulfur, simply replace reagent 1h with an aromatic thiol, such as 3-aminothiophenol and carry out the remaining steps of the Scheme.

Scheme 1




To produce other substitutions at R₃ or R₄ some of the products of Scheme 1 may be used. For example, to produce a compound where R₃ is hydrogen and R₄ is CH₃C(O)-, the six-membered ring intermediate **1e**, is treated with a base, such as barium hydroxide, at reflux in EtOH to give the free amine **2a**. The amine is subsequently treated with an acid anhydride, such as trifluoroacetic anhydride to give **2b**. This intermediate may be carried through the remaining steps of Scheme 1 to produce the desired compound.

Scheme 2



The products of Scheme 1 may be used to produce other compounds of the invention. For example, to produce compounds of type **3a**, treat compound **1j** with a phenyl isocyanate at room temperature over 24 h. To produce compounds of type **3b**, **1j** may be treated at room temperature with acid chloride derivatives such as benzoyl chloride. In order to produce thiols **3c**, compounds of type **1j** may be treated with isothiocyanates, such as phenylisothiocyanate at room temperature. As discussed earlier, if pure enantiomers are desired, they may be obtained by chromatography of the reactant, **1j** or the products.


Scheme 3



Yet another scheme (Scheme 4) makes use of the intermediate of Scheme 1. Treatment of the aldehyde, 1f, with a nitroaniline derivative 4a,

and NaCNBH₃ at room temperature gives the coupled intermediate 4b. This intermediate may be acylated with benzoyl chloride and a mild base such as triethylamine to give the N-acyl intermediate 4c. 4c may be treated with a reducing agent such as Pd/C to give the aniline compound 4d. This
5 compound may be coupled with a halogen derivative 4e, such as 3-chloropropylpiperidine, using DBU and an alcoholic solvent at reflux over 4 h to give a mixture of mono and di amine products.


Scheme 4



To prepare compounds of the invention where n is 1-3, products of Scheme 1 are used in Scheme 5. Intermediate 1f is treated with 3-(m-

hydroxyphenyl)propylamine, an aromatic amino alcohol derivative 5a, and NaCNBH₃ at room temperature over 16 h to give the amine 5b. Treatment of 5b with a thiocyanate derivative 5c, and a mild base at room temperature gives the substituted thioamide 5d. This compound may be treated with a
5 halide reagent, 5e, and a base such as DBU in an alcoholic solvent at reflux to give the O-substituted compound of the invention.

Scheme 5



10

The compounds of the invention were tested for their ability to compete with radiolabeled motilin (porcine) for the motilin receptors located on the

colon of mature rabbits. The colon from mature New Zealand rabbits was removed, dissected free from the mucosa and serosa layers, and diced into small pieces. The muscle tissues were homogenized in 10 volumes of buffer (50 mM Tris-Cl, 10 mM MgCl₂, 0.1 mg/mL bacitracin, and 0.25 mM Peflabloc, pH 7.5) in a Polytron (29,000 rpm, 4 x 15 seconds). The homogenate was centrifuged at 1000 xg for 15 min. and the supernatant discarded. The pellet was washed twice before being suspended in homogenizing buffer. This crude homogenate is then passed first through a 19 gauge needle then a 23 gauge needle to further suspend the material and stored as -80 °C. In a total volume of 0.50 mL, the binding assay contains the following components added sequentially, buffer (50 mM Tris-Cl, 10 mM MgCl₂, 1 mM EDTA, 15 mg/mL BSA, 5 µg/mL leupeptin, aprotinin, and pepstatin, and 0.1 mg/mL bacitracin), I¹²⁵ motilin (Amersham, ca 50,000-70,000 cpm, 25-40 pM), the test compound (the initial concentration was 2 mM/100% DMSO, which diluted with H₂O to a final concentration of 10 µM) and membrane protein (100-300 µg). After 30 min, at 30 °C, the material was cooled on ice and centrifuged at 13,000 xg for 1 minute. The pellet was washed with 1 mL 0.9% saline and centrifuged at 13,000 xg for 15 seconds. The pellet was washed again with cold saline and the supernatant was removed. The pellet was counted in the gamma counter to determine the percentage of unbound motilin and thereby the percent inhibition of the test compound. IC₅₀s were determined for some compounds by standard techniques.




Table A

	RWJ/Cpd.	R ₁	n	R ₂	R ₆	IC ₅₀ / % Inhibition
5	8	phenylNH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	20 nM **
	9	phenylNH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	>300 nM ***
	69	H	0	4-OH	H	11% @ 10 μM
	50	(CH ₂) ₂ NEt ₂	0	3-OH	H	81% @ 10 μM
	51	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ NEt ₂	H	0.6% @ 10 μM
10	52	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ piperidin-1-yl	H	0.6
	53	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ morpholin-1-yl	H	0.3
	54	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ piperidin-1-yl	H	0.9
	55	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ pyrrolidin-1-yl	H	0.9
	70	(CH ₂) ₂ NEt ₂	0	2-O(CH ₂) ₂ morpholin-1-yl	H	80% @ 10 μM
	71	(CH ₂) ₂ NEt ₂	0	4-S(CH ₂) ₂ NMe ₂	H	1.5
15	56	H	0	4-S(CH ₂) ₂ NMe ₂	H	85% @ 10 μM
	58	H	0	4-S(CH ₂) ₂ NEt ₂	H	1.8
	57	(CH ₂) ₂ - morpholin-1-yl	1	3-O(CH ₂) ₂ morpholin-1-yl	H	0.7
	72	(CH ₂) ₂ NEt ₂	0	2-O(CH ₂) ₂ morpholin-1-yl	H	0.9
20	73	(CH ₂) ₂ NEt ₂	0	2-OH	H	84% @ 10 μM
	74	(CH ₂) ₂ NEt ₂	0	4-OH	H	81% @ 10 μM
	75	H	0	3-NH ₂	H	41% @ 10 μM
	76	(CH ₂) ₂ NEt ₂	2	4-OH	H	84% @ 10 μM
	77	1-benzylpiperidin-4-yl	1	3-O(CH ₂) ₂ NEt ₂	H	0.8
25	58	H	0	3-S(CH ₂) ₂ NEt ₂	H	61% @ 10 μM
	78	CH ₃ C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	1.03
	10	phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	0.3
	6	H	0	3-O(CH ₂) ₂ morpholin-1-yl	H	37% @ 10 μM
	46	phenylC(O)	0	3-OCH ₂ CO ₂ Et	H	51 % @ 10 μM
30	79	phenylC(O)	0	3-S(CH ₂) ₂ NEt ₂	H	98% @ 10 μM

	22	phenylNH-C(O)	0	3-S(CH ₂) ₂ morpholin-1-yl	H	83% @ 10 μM
	80	4-F-phenyl-C(O)	0	3-S(CH ₂) ₂ morpholin-1-yl	H	79% @ 10 μM
	81	H	2	3-O(CH ₂) ₂ morpholin-1-yl	H	81% @ 10 μM
	82	phenylC(O)	0	3-S(CH ₂) ₂ morpholin-1-yl	H	80 % @ 10 μM
5	83	phenylC(O)	1	3-O(CH ₂) ₂ NEt ₂	H	100% @ 10 μM
	84	4-CH ₃ O-phenylC(O)	0	3-S(CH ₂) ₂ morpholin-1-yl	H	59 % @ 10 μM
	85	(CH ₂) ₂ - morpholin-1-yl	2	3-O-C(O)phenyl	H	9 % @ 2.0 μM
	86	phenylC(O)	0	4-S(CH ₂) ₂ N(CH ₃) ₂	H	49% @ 2.0 μM
10	40	H	0	3-O(CH ₂) ₂ morpholin-1-yl	4-OCH ₃	27% @ 10 μM
	87	H	0	3-OH	4-OCH ₃	32% @ 10 μM
	88	benzyl	1	3-O(CH ₂) ₂ morpholin-1-yl	H	94% @ 10 μM
	89	4-CH ₃ O-phenylNH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	26% @ 5.0 μM
	90	3-CH ₃ O-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	65% @ 0.5 μM
15	91	phenylC(O)	1	1-benzylpip- eridin-4-amino	H	77% @ 10 μM
	92	(CH ₂) ₂ NEt ₂	2	3-O(CH ₂) ₂ morpholin-1-yl	H	95% @ 10 μM
	32	phenylC(O)	1	3-O(CH ₂) ₂ morpholin-1-yl	H	70 % @ 10 μM
	59	4-F-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	52 nM
20	60	4-CH ₃ O-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	90 nM
	7	phenylNH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	45 nM
	93	benzyl	0	3-O(CH ₂) ₂ morpholin-1-yl	4-OCH ₃	62% @ 10 μM
	94	H	0	3-O(CH ₂) ₂ morpholin-1-yl	4-OCH ₃	48% @ 10 μM
	41	phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	4-OCH ₃	74% @ 10 μM
25	95	(CH ₂) ₂ - morpholin-1-yl	2	3-O-C(O)phenyl	4-OCH ₃	22% @ 2.0 μM
	34	phenylC(O)	2	3-O(CH ₂) ₂ morpholin-1-yl	H	82% @ 10 μM
	96	4-(CH ₃) ₂ N-phenylC(O)	2	3-O(CH ₂) ₂ morpholin-1-yl	H	62% @ 1.0 μM
	97	3,4-dichlorophenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	260 nM
30	98	4-F-phenylC(O)	0	3-(CH ₂) ₂ morpholin-1-yl	H	17 % @ 1.0 μM
	99	3,5-di-CF ₃ -phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	28 % @ 1.0 μM

	100	2,3,4,5,6-pentafluoro-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	1000 nM
	19	phenyl-NHC(O)	0	3-(CH ₂) ₃ morpholin-1-yl	H	59 % @ 1.0 μM
	61	4-Br-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	64% @ 0.05 μM
5	101	3-Br-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	54% @ 0.1 μM
	102	4-Cl-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	61% @ 0.1 μM
	103	3-CF ₃ -phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	52 % @ 0.1 μM
	104	4-CF ₃ -phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	29 % @ 0.1 μM
	105	4-I-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	59 % @ 0.1 μM
10	106	3,5-di-F ₂ -phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	78 % @ 0.1 μM
	62	3,4-di-F ₂ -phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	50 nM
	1407	4-(phenyl)phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	58% @ 1.0 μM
	108	thiophen-2-yl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	84% @ 1.0 μM
	11	phenylNH-C(S)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	45 % @ 0.1 μM
15	109	4-NC-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	98 nM
	110	4-t-butyl-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	19 % @ 1.0 μM
	111	pyridin-4-yl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	51% @ 1.0 μM
	63	3-F-phenyl-NHC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	37 nM
	112	3-Br-phenyl-NHC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	51% @ 1.0 μM
20	38	4-Br-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	6-Cl	59% @ 1.0 μM
	113	3-F-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	6-Cl	59% @ 1.0 μM
	114	3,4-diF-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	6-Cl	52% @ 100 μM
	115	2-Br-thiophen-1-yl-C(O)-	0	3-O(CH ₂) ₂ morpholin-1-yl	H	65% @ 1.0 μM
25	116	4-NO ₂ -phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	69% @ 0.1 μM
	117	di-phenyl-CH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	42% @ 1.0 μM
	118	phenyl-OC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	51% @ 1.0 μM
	119	cyclohexyl-NHC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	56% @ 1.0 μM




Table B

	Cpd.	R ₁	n	R ₂	IC ₅₀ / % Inhibition
5	120	4-F-phenyl-NH-C(O)	0	3-Cl-benzyl	10 nM
	121	4-F-phenyl-C(O)	0	3-Cl-benzyl	30 nM
	65	4-F-phenyl-C(O)	0	4-MeO-benzyl	56 nM
	66	phenyl-C(O)	0	4-MeO-benzyl	56 nM
	122	1,3-benzodioxol-5-yl-C(O)	0	benzyl	77% @ 1.0 μM
10	123	phenyl-NH-C(O)	0	(CH ₃) ₂ CH-	51% @ 1.0 μM
	124	naphthyl-1-yl-C(O)	0	benzyl	40% @ 0.1 μM
	125	4-F-phenyl-C(O)	0	4-F-benzyl	43% @ 0.04 μM
	126	3-F-phenyl-C(O)	0	4-F-benzyl	44% @ 0.04 μM
	67	phenyl-NHC(O)	0	4-F-benzyl	34% @ 0.25 μM
15	127	phenyl-NHC(O)	0	phenyl	33% @ 0.1 μM
	128	4-F-phenyl-C(O)	0	phenyl	43% @ 0.1 μM
	68	phenyl-NHC(O)	0	3-Cl-benzyl	70% @ 0.1 μM
	129	4-Br-phenyl-C(O)	0	3-Cl-benzyl	70% @ 0.1 μM
	130	3,4-di-F-phenyl-C(O)	0	3-Cl-benzyl	78% @ 0.1 μM

20




Table C

	Cpd.	R ₁	R ₂	R ₃	R ₅	IC ₅₀ / %
	<u>Inhibition</u>					
25	131	H	benzyl	CF ₃ C(O)	3-O(CH ₂) ₂ morpholin-1-yl	25 % @ 10 μM
	132	phenyl-C(O)	benzyl	CF ₃ C(O)	3-O(CH ₂) ₂ morpholin-1-yl	0.73 nM
	15	phenyl-NH-C(O)	benzyl	CH ₃ C(O)	3-O(CH ₂) ₂ morpholin-1-yl	40 % @ 1.0 μM

133	4-F-phenyl-C(O)	benzyl	CH ₃ C(O)	3-O(CH ₂) ₂ morpholin-1-yl	51 % @ 1.0 μM
134	phenyl-NH-C(O)	benzyl	CF ₃ C(O)	3-O(CH ₂) ₂ morpholin-1-yl	69 % @ 1.0 μM
135	(CH ₂) ₂ NEt ₂	(CH ₃)CH	CCl ₃ C(O)	3-O(CH ₂) ₂ N(CH ₃) ₂	1.6 nM




Table D

Cpd.	R ₁	IC ₅₀ / % Inhibition
136	phenyl-NH-C(O)	57% @ 1.0 μM
137	4-Br-phenyl-C(O)	50% @ 1.0 μM

Select compounds of the invention were evaluated for their ability to inhibit motilin and erythromycin induced contractions in the rabbit duodenum smooth muscle. Rabbits were fasted 24-48 h and euthanized. The ventral midline incision was made approximately 7.5 cm above the umbilicus upto the xyphoid process, exposing the upper peritoneal cavity. The first 8 cm. of the duodenum starting at the pyloric valve was quickly removed and placed in Krebs solution containing NaCl (120 m), KCl (4.7 mM), MgSO₄·7 H₂O (1.2 mM), CaCl₂·2 H₂O (2.4 mM), KH₂PO₄ (1 mM), D-glucose (10 mM), and NaHCO₃ (24 mM). The lumen was flushed with Krebs and excess tissue was removed. The tissue was cut lengthwise, splayed open with the longitudinal muscle layer facing up, and the longitudinal muscle layer was released away from the circular muscle and cut into 3x30 mm strips. A pre-tied 4-0 silk ligature with a loop was placed at the middle of the strip and the strip was folded over the loop so the strip was half its original length. The tissues were mounted in a 10 mL tissue bath (Radnoti Glass Technology, Inc., Monrovia, CA.) containing Krebs solution gassed with 95% O₂ 5% CO₂ at 37 °C. The tissues were attached to a force displacement transducer (FT03, Grass Instruments, Quincy, MA.) and resting tension was slowly increased to 1 g. The tissues were allowed to equilibrate for 60-90 min with 2-3 wash cycles.

The tissues were equilibrated with two initial contractions induced by a concentration of acetylcholine (1×10^{-4} M) that produced a maximal contraction (0.1 mM), with the highest taken as 100% maximal contraction of that tissue. Base line and response levels are expressed as grams tension developed and as a percent of the response to acetylcholine. The test compounds were dissolved in DMSO (2 mM/100% DMSO) and applied to the prepared strips 5-15 minutes prior to the addition of porcine motilin. After addition, the tension is constantly monitored over 5 min and the maximum tension is recorded. The percent contraction was measured at four ascending concentrations and where appropriate IC_{50} s were determined.




Table A

RWJ/Cpd.	R ₁	n	R ₂	R ₆	IC ₅₀ / % Inhibition
8	phenylNH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	280 nM **
15 9	phenylNH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	890 nM ***
50	(CH ₂) ₂ NEt ₂	0	3-OH	H	98% @ 20 μM
51	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ NEt ₂	H	74% @ 5 μM
52	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ piperidin-1-yl	H	70% @ 10 μM
53	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ morpholin-1-yl	H	3.93 mM
20 54	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ piperidin-1-yl	H	24% @ 5 μM
55	(CH ₂) ₂ NEt ₂	0	3-O(CH ₂) ₂ pyrrolidin-1-yl	H	43% @ 2 μM
56	H	0	4-S(CH ₂) ₂ NMe ₂	H	24% @ 2 μM
57	(CH ₂) ₂ - morpholin-1-yl	1	3-O(CH ₂) ₂ morpholin-1-yl	H	1.06
25 58	H	0	4-S(CH ₂) ₂ NEt ₂	H	44% @ 2.0 μM
10	phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	393 nM
59	4-F-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	54% @ 3.0 μM
60	4-CH ₃ O-phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	49% @ 10 μM
7	phenylNH-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	287 nM
30 61	4-Br-phenylC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	63% @ 1.0 μM

62	3,4-di-F ₂ -phenyl-C(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	65% @ 1.0 μM
63	3-F-phenyl-NHC(O)	0	3-O(CH ₂) ₂ morpholin-1-yl	H	63.8% @ 1.0 μM




Table B

Cpd.	R ₁	n	R ₂	IC ₅₀ / % Inhibition
65	4-F-phenyl-C(O)	0	4-MeO-benzyl	72% @ 1.0 μM
66	phenyl-C(O)	0	4-MeO-benzyl	58% @ 1.0 μM
67	phenyl-NHC(O)	0	4-F-benzyl	25.7% @ 1.0 μM
68	phenyl-NHC(O)	0	3-Cl-benzyl	51% @ 1.0 μM

Although the claimed compounds are useful as modulators of the motilin receptor, some compounds are more active than others. These compounds are particularly preferred.

The particularly preferred compounds are those where:

R₁ is phenylaminocarbonyl, phenylcarbonyl, substituted phenylaminocarbonyl, substituted phenylcarbonyl, and hydrogen;

R₂ is phenylC₁₋₅alkyl;

R₃ is hydrogen;

R₄ is trifluoromethylacetyl;

R₅ is O-(CH₂)₂-morpholin-1-yl;

R₆ is hydrogen;

n is 0; and

m is 1.

To prepare the pharmaceutical compositions of this invention, one or more compounds or salts thereof, as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide


variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, 5 flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding 10 solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will preferably contain per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 5 to about 500 mg of the active ingredient, although other unit dosages may be employed. 20

In therapeutic use for treating disorders of the gastrointestinal system in mammals, the compounds of this invention may be administered in an amount of from about 0.5 to 100 mg/kg 1-2times per day orally. In addition the compounds may be administered via injection at 0.1-10 mg/kg per day. 25 Determination of optimum dosages for a particular situation is within the capabilities of formulators.

In order to illustrate the invention, the following examples are included. These examples do not limit the invention. They are meant to illustrate and suggest a method of practicing the invention. Although there are other 30 methods of practicing this invention, those methods are deemed to be within the scope of this invention.

EXAMPLES

Example 1




Cpd. 1

- 5 A solution of 3-ethoxy-2-cyclohexen-1-one (125 g, 0.89 mol) in ether (500 mL) was added at room temperature to a solution of 2M benzyl magnesium chloride (800 mL) under N₂ and stirred for 6h. The resulting mixture was poured into a solution of 30% H₂SO₄ and stirred for 5 h. The resulting organic layer was separated, and the aqueous layer was extracted with
10 several portions of ether. The combined organic layer was dried (MgSO₄), and concentrated in vacuo to give compound 1 (161 g) as a colorless oil. NMR(CDCl₃): 3.45 (s, 2H, benzylic protons), 5.83 (bs, 1H, olefinic proton), 7.22 (m, 5H, aromatic protons).

15


Example 2



Cpd. 2

- A solution of compound 1 (161 g, 0.87 mol) in ether (700 mL) was slowly
20 added to a suspension of LAH (33 g, 0.87 mol) and ether (100 mL) at 0 °C under N₂. The resulting mixture was stirred overnight at ambient temperature and cooled to 0 °C. Saturated K₂CO₃ solution was added to quench the excess LAH, the mixture was filtered through Celite and washed with several portions of ether. The combined organic layers were dried (MgSO₄) and
25 concentrated in vacuo to give compound 2 (150 g) as a colorless oil. NMR(CDCl₃): 3.23 (s, 2H, benzylic protons), 4.20 (bs, 1H, CHOH), 5.52 (bs, 1H, olefinic proton), 7.22 (m, 5H, aromatic protons).

Example 3




Cpd. 3


- 5 A solution of compound 2 (132 g, 0.7 mol) in ether (500 mL) was added to a suspension of hexane washed 60% NaH (27 g, 0.7 mol) in ether (500 mL) at 0 C under N₂ and stirred for 1h. Trichloroacetonitrile (115 g, 0.8 mol) was slowly added and the resulting mixture was allowed to warm to ambient temperature and stirred overnight. The solvent was removed in vacuo,
10 hexane (1 L) was added and the mixture was cooled to 0 C. Methanol (150 mL) was added and the resulting solid was filtered through Celite. The organic solvent was removed in vacuo to give a crude intermediate (215 g). This intermediate was dissolved in xylene (1 L) and heated to reflux for 3 h under N₂. The solvent was removed in vacuo, ether (3 L) and the solid
15 precipitate was filtered to give compound 3 (106 g) as a white crystal: mp 105-06 °C; NMR(CDCl₃): 3.20 (Abq, J = 8 Hz, 2H), 5.92 (m, 2H, olefinic protons), 6.28 (bs, 1H, NH), 7.22 (m, 5H, aromatic protons).

20


Example 4



Cpd. 4




Cpd. 4a



Cpd. 4b

A solution of compound 3 (35 g, mmol) in methylene chloride (500 mL) was treated with ozone at -78 °C until the solution turned blue. The excess of ozone was removed with a stream of N₂, dimethyl sulfide (5 mL) was added and the mixture was allowed to warm to room temperature. TsOH-H₂O (3.0 g) was added and the resulting mixture was stirred for 48 h. The solvent was removed *in vacuo* and residue was dissolved in methylene chloride and treated with hexane. The resulting mixture was stirred for 2 h and the resulting solid was filtered. This solid was washed with hexane and dried in vacuum oven overnight to give compound 4 (21.8 g) as a racemic mixture: mp 162 °C. NMR(CDCl₃): 3.20 (Abq, J = 8 Hz, 2H), 6.85 (bs, 1H, NH), 7.05 (s, 1H, olefinic proton), 7.22 (m, 5H, aromatic protons). 9.91 (s, 1H, CHO). Compound 4 was separated into the pure enantiomers 4a, and 4b by using a chiral column.


Example 5




Cpd. 5

A mixture of 3-hydroxyaniline (20.1 g, 190 mmol) K₂CO₃ (38 g) and EtOH (300 mL) was stirred at 60 °C for 6 h under N₂. The mixture was cooled to room temperature and 2-chloroethylmorpholine (16 g, mmol) was added. The resulting mixture was heated to reflux for 7 h, cooled to room temperature, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel using 3 MeOH/ ethyl acetate to give compound 5 as a brown oil (22.5 g).


Example 6



Cpd. 6



Cpd. 6a




Cpd. 6b

NaCNBH₄ (1.0 g) was added in three portions to a solution of compound 4 (7.3 g, 21.0 mmol), compound 5 (6.2 g, 27.9 mmol) acetic acid (5.5 mL) in methanol (300 mL) at room temperature under N₂ and stirred for 30 min. Most of methanol was removed in vacuo and the residue was diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel using ethyl acetate: hexane 9:1 to give compound 6 (10.3 g) as a light brown oil. NMR(CDCl₃): 3.20 (Abq, J = 8 Hz, 2H), 5.63 (s, 1H, olefinic proton), 6.61 (bs, 1H, NH). This racemic mixture was separated by HPLC using a chiral column (CHIRALCEL®OD™) and isopropanol and hexane (1:1) as an eluent into 6a and 6b. The oxalate salt of racemic 6, mp 90-92 °C. MS (MH⁺ = 552)

Example 7

3-Benzyl-3-trichloroacetyl-amino-1-(*N*-phenylaminocarbonyl)-*N*-[(3-(2-morpholinoethoxy)phenyl)amino]methylcyclopentene



5


Cpd. 7

To a solution of compound 6 (10.1 g) and triethylamine (0.1 mL) in methylene chloride (300 mL) was added phenyl isocyanate (7.8 g, mmol) at room temperature under N₂ dropwise. The resulting mixture was stirred for 24 h and most of solvent was removed in vacuo. The oily residue was purified by column chromatography on silica gel using ethyl acetate hexane 95:5 as an eluent to give an oil (12.5 g). NMR(CDCl₃): 3.17 (Abq, J = 8 Hz, 2H), 3.73 (m, 4H, CH₂NCH₂) 4.08 (t, 2H OCH₂-) 5.92 (m, 2H, olefinic protons), 6.28 (bs, 1H, NH), 7.22 (m, 5H, aromatic protons).

Treatment of the oil with 1N HCl in ether gives compound 7, the title compound (12.2) as a solid: mp. 70-73(dec.) MS 657(MH⁺)

Example 8

3-Benzyl-3-trichloroacetyl-amino-1-(*N*-phenylaminocarbonyl)-*N*-[(3-(2-morpholinoethoxy)phenyl)amino]methylcyclopentene



20

Cpd. 8


To a solution of compound 6b (15 mg) and triethylamine (1 drop) in methylene chloride (5 mL) was added phenyl isocyanate (16 mg) at room temperature under N₂ dropwise. The resulting mixture was stirred for 24 h and most of solvent was removed in vacuo. The oily residue was purified by

preparative TLC on silica gel using ethyl acetate hexane 95:5 as an eluent to give an oil. Treatment the oil with oxalic acid (or HCl) in ether gives compound 8, the title compound (15 mg) as a solid: mp 92-94 °C. MS (MH⁺= 671)

5

Example 9

3-Benzyl-3-trichloroacetyl-amino-1-(*N*-phenylaminocarbonyl)-*N*-[(3-(2-morpholinoethoxy)phenyl)amino]methylcyclopentene



10


Cpd. 9

To a solution of compound 6a (14 mg) and triethylamine (1 drop) in methylene chloride (5 mL) was added phenyl isocyanate (14 mg) at room temperature under N₂ dropwise. The resulting mixture was stirred for 24 h and most of solvent was removed in vacuo. The oily residue was purified by preparative TLC on silica gel using ethyl acetate hexane 95:5 as an eluent to give an oil. Treatment the oil with oxalic acid in ether gives compound 9, the title compound (14 mg) as a solid.

20

Example 10

3-Benzyl-3-trichloroacetyl-amino-1-(*N*-phenylcarbonyl)-*N*-[(3-(2-morpholinoethoxy)phenyl)amino]methylcyclopentene



25


Cpd. 10

Benzoyl chloride (31 mg) was added to a solution of compound 6 (55 mg) and triethylamine (0.3 mL) in methylene chloride (30 mL) at room temperature under N₂ and stirred for 2 hours. Most of solvent was removed in vacuo and the oily residue was purified by column chromatography on silica gel using ethyl acetate as an eluent to give a light brown oil (53 mg). This oil was treated with oxalic acid in ether to give the title compound as an off-white powder (47 mg); mp 79-81 °C. MS (MH⁺ = 656)

10

Example 11

3-Benzyl-3-trichloroacetyl-amino-1-(N-phenylaminosulfonyl)-N-[(3-(2-morpholinoethoxy)phenyl)amino]methylcyclopentene




Cpd. 11

- 15 Phenyl isothiocyanate (15 mg) was added dropwise to a solution of compound 6 (30 mg) and triethylamine (1 drop) in methylene chloride (5 mL) at room temperature under N₂. The resulting mixture was stirred for 24 h and most of solvent was removed in vacuo. The oily residue was purified by prep TLC on silica gel using ethyl acetate hexane 95:5 as an eluent to give an oil.
- 20 Treatment the oil with 1N HCl in ether gives compound 11, the title compound (33 mg), as a solid; mp 105-108 °C. MS (MH⁺ = 687)

25


Example 11



Cpd. 11

A mixture of compound 3 (3.5 g), barium hydroxide (4 g) and EtOH (100 mL) was heated at reflux overnight. The mixture was cooled to room temperature, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel using 1% triethylamine/ethyl acetate as an eluent to give compound 11 as a pale yellow oil (1.1 g). NMR; 2.72 (Abq, J = 8 Hz, 2H, benzylic protons), 5.54 (bd, J = 9 Hz, 1H, olefinic proton at 2 position), 5.63(dt, 1 H, the other olefinic proton), 7.23 (m, 5H, aromatic protons).


Example 12



Cpd. 12

A mixture of compound 9 (should be 11) (350 mg) triethylamine (200 mg), acetic anhydride (200 mg) and methylene chloride (50 mL) was stirred at room temperature under N₂ for 3h. The mixture was diluted with methylene chloride (50 mL) and poured into ice cold 1 N NaOH (50 mL). The organic layer was separated, dried and the solvent was removed in vacuo to give compound 12 (376 mg) as a pale yellow oil. NMR(CDCI₃): 1.94 (s, 3H, acetyl), 3.10 (Abq, J = 8 Hz, 2H), 5.92 (m, 2H, olefinic protons), 6.28 (bs, 1H, NH), 7.22 (m, 5H, aromatic protons).


Example 13



Cpd. 13

A solution of compound 12 (376 mg) in methylene chloride (100 mL) was treated with ozone at -78 °C until the solution turned blue. The excess of ozone was removed with a stream of N₂, dimethyl sulfide (0.5 g) was added and the mixture was allowed to warm to room temperature. TsOH-H₂O (100 mg) was added and the resulting mixture was stirred for 4 days. The mixture was poured into ice cold 1N NaOH (50 mL) and the resulting organic layer was separated and purified by column chromatography on silica gel using ethyl acetate and hexane (1:5) as an eluent to give compound 13 (273 mg) as an oil. NMR(CDCl₃): 1.96 (s, 3H, acetyl), 3.20 (Abq, J = 8 Hz, 2H), 6.85 (bs, 1H, NH), 7.03 (s, 1H, olefinic proton), 7.22 (m, 5H, aromatic protons). 9.85 (s, 1H, CHO).

Example 14




Cpd. 14

NaCNBH₄ (150 mg) was added in three portions to a solution of compound 13 (273 mg), compound 5 (297 mg) acetic acid (0.5 mL) in methanol (50 mL) at room temperature under N₂ and stirred for 30 min. Most of methanol was removed in vacuo and the residue was diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel using ethyl acetate:MeOH:triethylamine (100:1:0.5) to give compound 14 (303 mg) as a light brown oil NMR; 1.88 (s, 3H, acetyl) 3.13 (Abq, J = 8 Hz, 2H, benzylic protons), 4.10 (t, J = 6Hz, 2H, phoxymethylene protons), 5.62 (bs, 1H, olefinic proton),

Example 15

3-Benzyl-3-acetylamino-1-(*N*-phenylaminocarbonyl)-*N*-[(3-(2-morpholinoethoxy)phenyl)amino]methylcyclopentene



5


Cpd. 15

To a solution of compound 14 (25 mg) and triethylamine (1 drop) in methylene chloride (5 mL) was added phenyl isocyanate (14 mg) at room temperature under N_2 . The resulting mixture was stirred for 24 h and most of solvent was removed *in vacuo*. The oily residue was purified by prep TLC on silica gel using ethyl acetate hexane 95:5 as an eluent to give an oil. Treatment the oil with oxalic acid in ether gives compound 15, the title compound (33 mg) as a solid: mp 85-89 °C. MS (MH^+ = 569)

15

Example 16

Preparation of Compound 16




Cpd. 16

A solution 1N BH_3 /THF (20 mL) was added to a solution of 3-(3-aminophenyl)propionic acid (1.5 g) in THF (15 mL) at 0 °C under N_2 . After addition the mixture was allowed to warm up to room temperature and was stirred overnight. 2N NaOH was carefully added, the resulting mixture was stirred for 4 h and most of the solvent was removed *in vacuo*. The residue was extracted with methylene chloride (200 mL) and the organic layer was dried and concentrated *in vacuo* to give compound 16 as a light yellow oil (1.1 g). NMR($CDCl_3$): 3.71 (t, J = 6Hz, 2H, CH_2OH), 6.72~7.13 (m, 4H, aromatic protons).

Example 17

Preparation of Compound 17




Cpd. 17

- 5 NaCNBH₄ (30 mg) was added in three portions to a solution of compound 4 (150 mg), compound 16 (100 mg) and acetic acid (10 drops) in methanol (25 mL) at room temperature under N₂ and stirred for 30 min. Most of methanol was removed in vacuo and the residue was diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and
- 10 residue was purified by column chromatography on silica gel using ethyl acetate:hexane (1:1) to give compound 15 (201 mg) as a pale yellow oil. NMR(CDCl₃); 3.16 (Abq, J = 8 Hz, 2H, benzylic protons), 3.72 (t, J = 6 Hz, 2H, CH₂OH), 3.82 (s, 2H, CH₂N), 5.62 (s, 1H, olefinic proton), 6.50~7.25 (m, 9H, aromatic protons).

15

Example 18



Cpd. 18

- Mesyl chloride (46 mg) was added to a solution of compound 17 (2.01 mg) and triethylamine (0.2 mL) in methylene chloride (50 mL) at -5 °C under N₂. This mixture was stirred for 5 min and MeOH (2 drops) was added and the resulting mixture was allowed to warm to room temperature and poured into 1N NaOH (10 mL). The organic layer was separated, dried and the solvent was removed in vacuo to give a thick brown oil. This oil was dissolved in THF


(10 mL) and morpholine (50 mg) and the resulting mixture was heated at reflux for 16 h.

The mixture was cooled to room temperature and the solvent was removed in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate:triethylamine (100:0.5) to give compound 18 (85 mg) as a pale yellow oil. NMR(CDCl₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 3.82 (s, 2H, CH₂N), 5.62 (s, 1H, olefinic proton), 6.50~7.25 (m, 9H, aromatic protons).

10

Example 19

3-Benzyl-3-trichloroacetyl-amino-1-(N-phenylaminocarbonyl)-N-[(3-(3-morpholinopropyl)phenyl)amino]methylcyclopentene




Cpd. 19

15 To a solution of compound 18 (32 mg) and triethylamine (1 drop) in methylene chloride (5 mL) was added phenyl isocyanate (25 mg) at room temperature under N₂ dropwise. The resulting mixture was stirred for 24 h and most of solvent was removed in vacuo. The oily residue was purified by preparative TLC on silica gel using ethyl acetate hexane 95:5 as an eluent to give an oil (41 mg). Treatment of the oil with oxalic acid in ether gives
20 compound 19, the title compound (40 mg) as a solid: mp 85-88 °C. MS (MH⁺ = 669)

25


Example 20



Cpd. 20

A mixture of 3-aminothiophenol (1.25 g, 10.0 mmol), 2-chloroethylmorpholine (2.3 g, 12.0 mmol) and K_2CO_3 (1.8 g) in THF (150 mL) was heated to reflux
5 for 8 h. The resulting mixture was filtered and partitioned between H_2O and ethyl acetate. The aqueous layer was washed with several portions of ethyl acetate and the combined organic extracts were dried Na_2SO_4 and concentrated in vacuo. The residue was purified by column chromatography on silica gel using 10% MeOH/ethyl acetate as an eluent to give compound
10 20 as an oil (600 mg). NMR($CDCl_3$); 2.60 (t, $J = 6$ Hz, 2H, CH_2N), 3.02 (t, $J = 6$ Hz, 2H, CH_2S), 6.44~7.06 (m, 4H, aromatic protons).

Example 21




Cpd. 21

15 $NaCNBH_4$ (300 mg) was added in three portions to a solution of compound 4 (800 mg), compound 20 (600 mg), and acetic acid (2.0 mL) in methanol (100 mL) at room temperature under N_2 . The reaction mixture was stirred for 30 min, most of methanol was removed in vacuo. The residue was diluted with
20 methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel using ethyl acetate: MeOH:triethylamine (100:2:0.1) to give compound 21 (735 mg) as a pale yellow oil. NMR($CDCl_3$); 3.18 (Abq, $J = 8$ Hz, 2H, benzylic protons), 3.82 (s, 2H, CH_2N), 5.62 (s, 1H, olefinic proton),
25 6.50~7.25 (m, 9H, aromatic protons). MS ($MH^+ = 568$)

Example 22


3-Benzyl-3-trichloroacetyl-amino-1-(*N*-phenylaminocarbonyl)-*N*-[(3-(2-morpholinoethyl)phenyl)thio]methylcyclopentene



Cpd. 22

To a solution of compound 18 (53 mg) and triethylamine (1 drop) in methylene chloride (30 mL) was added phenyl isocyanate (38 mg) at room temperature under N_2 dropwise. The resulting mixture was stirred for 24 h and most of solvent was removed *in vacuo*. The oily residue was purified by column chromatography on silica gel using ethyl acetate:triethylamine (100:0.2) as an eluent to give an oil (55 mg). Treatment the oil with oxalic acid in ether gives compound 19, the title compound (57 mg) as a white solid: mp 88-92 °C. MS (MH^+ = 687)

Example 23




Cpd. 23

$NaCNBH_4$ (589 mg) was added in three portions to a solution of compound 4 (2.0 g), 3-nitroaniline (1.59 g, 11.5 mmol) acetic acid (2 mL) in methanol (100 mL) at room temperature under N_2 , and stirred overnight. Most of methanol was removed *in vacuo* and the residue was diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed *in vacuo* and

residue was purified by column chromatography on silica gel using ethyl acetate:hexane 1:1 to give compound 23 (2.0 g) as a pale yellow oil. NMR(CDCl₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 3.85 (d, J = 6Hz, 2H, CH₂N), 5.62 (s, 1H, olefinic proton), 6.80~7.44 (m, 9H, aromatic protons).

Example 24




Cpd. 24

10 Benzoyl chloride (125 mg, 0.89 mmol) was added to a solution of compound 23 (350 mg, 0.748 mmol) and triethylamine (1.3 mg) in methylene chloride (30 mL) at room temperature under N₂ and this mixture was stirred for 2 h. Most of solvent was removed in vacuo and the oily residue was purified by column chromatography on silica gel using ethyl acetate:hexane (1:4) as an eluent to give compound 24 as a light brown oil (350 mg). NMR(CDCl₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 4.65 (d, J = 8Hz, 2H, CH₂N), 5.62 (s, 1H, olefinic proton), 6.08~8.01 (m, 14H, aromatic protons).

20

Example 25




Cpd. 25


A mixture of compound 24 (350 mg, 0.61 mmol), 10% Pd/C (5 mg) and acetic acid (2 drops) in EtOH (20 mL) was hydrogenated at 50 psi at room temperature for 8 h. The resulting mixture was filtered through Celite and

concentrated in vacuo. The residue was treated with methylene chloride (300 mL) washed with H₂O, dried and the solvent was removed in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate as an eluent to give compound 25 (200 mg) as an oil. NMR(CDCI₃);
 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 4.58 (d, J = 8Hz, 2H, CH₂N), 5.62
 (s, 1H, olefinic proton), 6.28-7.41 (m, 14H, aromatic protons).

Example 26



Cpd. 23a




Cpd. 23b

A solution of compound 25 (160 mg, 0.3 mmol), chloroethylmorpholine (82 mg, 0.44 mmol), and DBU (101 mg) in 2-propanol (25 mL) was heated to reflux for 2 days. The solvent was removed in vacuo and the residue was treated with 0.5 N NaOH (100 mL) and extracted with several portions of ethyl acetate. The organic layer was dried concentrated in vacuo. The residue was purified by column chromatography on silica gel. The bis-alkylated compound (84 mg) was eluted with ethyl acetate:MeOH 95:5. This compound was treated with oxalic acid and ether to give compound 23a (70 mg) as a solid. mp 86-92 °C. MS (MH⁺ = 655)

Continued elution with methylene chloride:MeOH:triethylamine 85:10:5) to give the mono-alkylated product 23b, which was converted to the oxalate salt with oxalic acid and ether (40 mg). mp 88-96 °C. MS (MH^+ = 768)

5

Example 27




Cpd. 27

NaCNBH₄ (146 mg) was added in three portions to a solution of 4-chlorobenzaldehyde (308 mg, 2.2 mmol), 3-aminophenol (200 mg, 1.83 mmol) acetic acid (1.0 mL) in methanol (100 mL) at room temperature under N₂ and stirred for 30 min. Most of methanol was removed in vacuo and the residue was diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel using ethyl acetate to give compound 27 (230 mg) as a pale yellow oil. NMR(CDCI₃); 4.26 (s, 2H, benzylic protons), 6.10~7.24 (m, 8H, aromatic protons). MS (MH^+ = 234)

15

Compound 28




Cpd. 28

20

NaCNBH₄ (60 mg) was added in three portions to a solution of compound 4 (259 mg), compound 27 (230 mg.) and acetic acid (1.0 mL) in methanol (50 mL) at room temperature under N₂ and stirred for 16 h. Most of methanol was removed in vacuo and the residue was diluted with methylene chloride,

washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel to give compound 28 (100 mg) as an oil. NMR(CDCI₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 4.00 (d, J = 8Hz, 2H, CH₂N), 4.42(s, 2H, 4-chlorobenzyl protons), 5.42 (s, 1H, olefinic proton), 6.21~7.25 (m, 13H, aromatic protons).


Example 29



Cpd. 29

A solution of compound 28 (100 mg, 0.18 mmol), chloroethylmorpholine (100 mg, 0.6 mmol), and DBU (115 mg) in 2-propanol (50 mL) was heated to reflux for 2 days. The solvent was removed in vacuo and the residue was treated with 0.5 N NaOH (100 mL) and extracted with several portions of ethyl acetate. The organic layer was dried concentrated in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate:hexane (1:1) to give an oil (95 mg). Treatment of the oil with oxalic acid and ether gives compound 29, the title compound as a solid:mp 134-136. MS (MH⁺ = 676)


Example 30



Cpd. 30

NaCNBH₄ (35.3 mg) was added in three portions to a solution of compound 4 (150 mg, 0.43 mmol), 3-hydroxybenzylamine (104.8 mg, 0.87 mmol) acetic acid (1.0 mL) in methanol (50 mL) at room temperature under N₂ and stirred for 16 h. Most of methanol was removed in vacuo and the residue was diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel to give compound 30 (160 mg) as an oil. NMR(CDCl₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 3.38 (s, 2H, 3-hydroxybenzyl protons), 3.72 (d, J = 8 Hz, 2H, CH₂N), 5.62 (s, 1H, olefinic proton), 6.68~7.25 (m, 9H, aromatic protons).


Example 31



Cpd. 31

Benzoyl chloride (69 mg, 0.5 mmol) was added to a solution of compound 30 (150 mg, 0.33 mmol) and triethylamine (1.0 mL) in methylene chloride (20 mL) at room temperature under N₂ and stirred for 16 h. Most of solvent was removed in vacuo and the oily residue was purified by column chromatography on silica gel using ethyl acetate:hexane 1:4 as an eluent to give compound 31 as a light brown oil (220 mg). NMR(CDCl₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), , 5.59 and 5.62, (both s, 1H total, olefinic proton, two rotamer?), 6.60~8.15 (m, 14H, aromatic protons).


Example 32



Cpd. 32

A solution of compound 31 (220 mg, 0.4 mmol), chloroethylmorpholine (280 mg, 1.4 mmol), and DBU (120 mg) in 2-propanol (100 mL) was heated to reflux for 16 h. The solvent was removed in vacuo and the residue was treated with 0.5 N NaOH (100 mL) and extracted with several portions of ethyl acetate. The organic layer was dried concentrated in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate:MeOH (9:1) to give an oil (95 mg). Treatment of the oil with oxalic acid and ether gives compound 32, the title compound as a solid:mp 90-95. MS (MH^+ = 670)


Example 33



Cpd. 33

Benzoyl chloride (280 mg) was added to a solution of compound 24 (300 mg) and triethylamine (2.0 mL) in methylene chloride (30 mL) at room temperature under N_2 and stirred for 2 hours. Most of solvent was removed in vacuo and the oily residue was purified by column chromatography on silica gel using ethyl acetate:hexane 1:4 as an eluent. to give compound 33 as a light brown oil (265 mg). NMR($CDCl_3$): 3.18 (Abq, $J = 8$ Hz, 2H, benzylic protons), 3.35 (s, 2H, allylic methylene protons) 5.61 (s, 1H, olefinic proton) 6.60~7.23 (m, 9H, aromatic protons). MS (MH^+ = 467)


Example 34 (two -step procedure)



Cpd. 34

A solution of compound 33 (265 mg, 0.46 mmol), chloroethylmorpholine (173 mg, 0.8 mmol), and DBU (107 mg) in 2-propanol (50 mL) was heated to reflux for 16 h. The solvent was removed in vacuo and the residue was treated with 0.5 N NaOH (100 mL) and extracted with several portions of ethyl acetate. The organic layer was dried concentrated in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate:MeOH (95:5) to give an oil (165 mg). Treatment of the oil with oxalic acid and ether gives compound 34, the title compound as a solid:mp 126-28 °C. MS (MH⁺ = 684)


Example 35



Compound 35

A solution of 4-chloro-3-nitrophenol (2.0 g, 11.53 mmol), chloroethylmorpholine (2.57 g, 13.8 mmol), and K₂CO₃ (5.0 g) in 2-propanol (200 mL) was heated to reflux for 16 h. The solvent was removed in vacuo and the residue was treated with 0.5 N NaOH (100 mL) and extracted with several portions of ethyl acetate. The organic layer was dried and concentrated in vacuo to give compound 35 as an oil. NMR(CDCl₃): 4.18 (t, J = 6 Hz, 2H, phoxymethylene protons), 7.09-7.44 (m, 3H, aromatic protons).


Example 36



A mixture of compound 35 (500 mg, 1.84 mmol), 10% Pd/C (5 mg) and acetic acid (2 drops) in EtOH (20 mL) was hydrogenated at 55 psi at room temperature for 16 h. The resulting mixture was filtered through Celite and concentrated in vacuo. The residue was treated with methylene chloride (300 mL) washed with H₂O, dried and the solvent was removed in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate:MeOH (95:5) as an eluent to give compound 36 (200 mg) as an oil.

10 NMR(CDCl₃); 4.06 (t, J = 6 Hz, 2H, phenoxymethylene protons), 6.35–7.10 (m, 3H, aromatic protons).

Example 37




Cpd. 37

15 NaCNBH₄ (53 mg) was added in three portions at room temperature under N₂ to a solution of compound 4 (243 mg, 0.7 mmol), compound 36 (200 mg, 0.78 mmol), and acetic acid (2.0 mL) in methanol (75 mL). This mixture was stirred for 16 h and most of methanol was removed in vacuo. The residue was

20 diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel using ethyl acetate:MeOH (95:5) as an eluent to give compound 37 (250 mg) as an oil. NMR(CDCl₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 4.08 (t, J = 6Hz, 2H, phenoxymethylene protons), 5.62 (s,

25 1H, olefinic proton), 6.22–7.30 (m, 8H, aromatic protons).

Example 38




Example 38

Cpd. 38

4-Bromobenzoyl chloride (25 mg) was added to a solution of compound 37 (45 mg) and triethylamine (1.0 mL) in methylene chloride (25 mL) at room temperature under N_2 . The reaction mixture was stirred for 16 h and most of solvent was removed in vacuo. The oily residue was purified by preparative TLC using ethyl acetate as an eluent to give an oil (25 mg). Treatment of the oil with oxalic acid in ether gives compound 38 (20 mg). MS (MH^+ = 768)

Example 39



Cpd. 39

$NaCNBH_4$ (204 mg) was added in three portions to a solution of compound 4 (1.04 g, 3.0 mmol), 3-hydroxy-4-methoxyaniline (835 mg, 6.1 mmol), and acetic acid (2.0 mL) in methanol (100 mL) at room temperature under N_2 . The reaction mixture was stirred for 6 h and most of methanol was removed in vacuo. The residue was diluted with methylene chloride, washed with 1N. NaOH and dried. The solvent was removed in vacuo and residue was purified by column chromatography on silica gel using ethyl acetate:hexane (1:1) as an eluent to give compound 39 (1.2 g) as an oil. NMR($CDCl_3$); 3.18

3

COc1ccc(N(CCN2CCOCC2)Cc3ccccc3C4C(=C(C=C4)NC(=O)OC(=O)C)C5C=CC=C5)cc1OCCN6CCCCC6

10

15


COc1cc(O)ccc1N(Cc2ccccc2C(=O)N(C)(C)C)Cc3ccccc3C(=O)N(C)(C)C

20

Benzoyl chloride (43 mg, 0.3 mmol) was added to a solution of compound 40 (120 mg, 0.26 mmol) and triethylamine (1.0 mL) in methylene chloride (50 mL) at room temperature under N₂. The mixture was stirred for 6 h, poured into

1N NaOH and extracted with methylene chloride. The organic extracts were combined, dried, and concentrated in vacuo. The oily residue was purified by column chromatography on silica gel using ethyl acetate:hexane (1:1) as an eluent to give compound 41 an oil (100 mg). NMR(CDCI₃); 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 3.81(s, 3H, CH₃O), 4.60 (d, J = 8Hz, 2H, CH₂N), 5.62 (s, 1H, olefinic proton), 6.60~7.38 (m, 13H, aromatic protons).


Example 42



Cpd. 41

10 A solution of compound 41 (100 mg, 0.17 mmol), chloroethylmorpholine (64.7 mg, .35 mmol), and DBU (300 mg) in 2-propanol (50 mL) was heated to reflux for 16 h. The solvent was removed in vacuo and the residue was treated with 0.5 N NaOH (100 mL) and extracted with several portions of ethyl acetate. The organic layer was dried concentrated in vacuo. The residue was purified
15 by column chromatography on silica gel using ethyl acetate:MeOH (9:1) to give an oil. Treatment of the oil with oxalic acid and ether gives compound 42 (81 mg), the title compound as a solid:mp 85-91 °C. MS (MH⁺ = 686)

Example 42




Cpd. 42

NaCNBH₄ (250 mg) was added in three portions to a solution of compound 4 (510 mg, 1.6 mmol), 3-aminophenol (515 mg, 4.9 mmol) acetic acid (1.0 mL) in methanol (200 mL) at room temperature under N₂. The reaction mixture
25 was stirred for 30 min and most of the methanol was removed in vacuo. The

residue was diluted with methylene chloride, washed with 1N. NaOH, dried and concentrated in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate:hexane (1:2) as an eluent to give compound 42 (385 mg) as a pale yellow oil. NMR(CDCI₃): 3.18 (Abq, J = 8 Hz, 2H, benzylic protons), 3.80 (ABq, J = 8Hz, 2H, CH₂N), 5.62 (s, 1H, olefinic proton), 6.21~7.25 (m, 9H, aromatic protons).


Example 43



Cpd. 43

A mixture of compound 42 (251 mg), K₂CO₃ (1.1 g) ethylbromoacetate (200 mg) THF (70 mL) was heated to 50 °C for 8 h. The resulting mixture was filtered through Celite and concentrated in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate:hexane (1:3) to give compound 43 a as a pale yellow oil (263 mg). Treatment of the oil with concentrated HCl and MeOH gives compound 43 as a white foam (89 mg): mp 64-66 °C. MS (MH⁺= 525)

Example 45




Cpd 45

A solution of compound 43a (59 mg), 1N NaOH (1 mL) in MeOH (5 mL) was stirred at room temperature under N₂ for 3 h. Most of the MeOH was removed in vacuo and the residue was diluted with H₂O (10 mL). This mixture was acidified to pH 4 using 0.1N HCl and extracted with methylene chloride. The combined organic extracts were dried and concentrated in vacuo to give

compound 45, the title compound as a light brown powder (35 mg): mp 70-73 °C. MS (MH^+ = 497)

Example 46




Cpd 46

5 Benzoyl chloride (31 mg) was added to a solution of compound 43a (45 mg) and triethylamine (0.1 mL) in methylene chloride (30 mL) at room temperature under N_2 and stirred for 5 h. The resulting mixture was poured into 1N NaOH and extracted with methylene chloride. The combined organic extracts were
10 combined, dried and concentrated in vacuo. Most of solvent was removed in vacuo and the oily residue was purified by using ethyl acetate:hexane (3:5) as an eluent, to give compound 46 as a pale yellow oil (100 mg). MS (MH^+ = 629)

CLAIMS

What is claimed is:

1. A compound of the Formula I:



wherein

10

R_1 is selected from hydrogen, C_{1-5} alkyl, substituted C_{1-5} alkyl (where the alkyl substituents are one or more halogens), amino C_{1-5} alkyl, C_{1-5} alkylamino C_{1-5} alkyl, di- C_{1-5} alkylamino C_{1-5} alkyl, $R_aR_bN-C_{1-5}$ alkyl (where the R_a and R_b are independently selected from hydrogen and C_{1-5} alkyl, or are taken together to form a morpholine, piperazine, piperidine, or N-substituted piperidine where the N- substituent is C_{1-5} alkyl or phenyl C_{1-5} alkyl), C_{1-5} alkylcarbonyl, C_{1-5} alkoxycarbonyl, aminocarbonyl, C_{1-9} alkylaminocarbonyl, cyclo C_{3-9} alkylaminocarbonyl, pyridinylcarbonyl, substituted pyridinylcarbonyl (where the pyridinyl substituents are selected from the group consisting of one or more halogens and C_{1-5} alkyl), thiophenecarbonyl, substituted thiophenecarbonyl (where the thiophene substituents are selected from the group consisting of one or more halogens and C_{1-5} alkyl), phenyl, phenyl C_{1-5} alkyl, phenoxycarbonyl, phenylcarbonyl, diphenylmethylcarbonyl, phenylaminocarbonyl, phenylthiocarbonyl, phenylaminothiocarbonyl, substituted phenyl, substituted phenyl C_{1-5} alkyl, substituted phenoxycarbonyl, substituted phenylcarbonyl, substituted phenylaminocarbonyl, substituted diphenylmethylcarbonyl, substituted phenylthiocarbonyl, and

20

25

substituted phenylaminothiocarbonyl (where the phenyl substituents are selected from the group consisting of one or more of halogen, C₁₋₅alkyl, trihalomethyl, C₁₋₅alkoxy, amino, nitrile, nitro, C₁₋₅alkylamino, di-C₁₋₅alkylamino, if there are more than one substituents they may be taken together with the phenyl ring to form a fused bicyclic 7-10 membered heterocyclic ring having one to two heteroatoms selected from oxygen, sulfur or nitrogen or the substituents may be taken together to form a fused bicyclic 7-10 membered aromatic ring;

R₂ is selected from hydrogen, C₁₋₅alkyl, C₁₋₅alkoxy, phenyl, substituted phenyl (where the phenyl substituents are selected from one or more of the group consisting of halogen and C₁₋₅alkyl), phenylC₁₋₅alkyl, substituted phenylC₁₋₅alkyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C₁₋₅alkyl, C₁₋₅alkoxy, halo and di-C₁₋₅alkylamino)

R₃ is selected from hydrogen, C₁₋₅alkylcarbonyl, substituted C₁₋₅alkylcarbonyl (where the alkyl substituents are selected from one or more halogens), phenylcarbonyl, and substituted phenylcarbonyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C₁₋₅alkyl, C₁₋₅alkoxy, amino, C₁₋₅alkylamino, and di-C₁₋₅alkylamino)

R₄ is selected from hydrogen, C₁₋₅alkylcarbonyl, substituted C₁₋₅alkylcarbonyl (where the alkyl substituents are selected from one or more halogens), phenylcarbonyl, and substituted phenylcarbonyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C₁₋₅alkyl, C₁₋₅alkoxy, amino, C₁₋₅alkylamino, and di-C₁₋₅alkylamino)

n is 0-3;

m is 1-5

R₅ is $X-(CH_2)_q-(A)_t$

where:

q is 0-2;

t is 0-1;

X is oxygen, CH₂, sulfur, or NR_c where

R_c is hydrogen, C₁₋₅alkyl, morpholinoC₁₋₅alkyl,

piperidinylC₁₋₅alkyl, N-phenylmethylpiperidinyl or

5 piperazinylC₁₋₅alkyl,

with the proviso that if q and t are 0, then X is hydroxy, thiol, or amino,

A is C₁₋₅alkoxycarbonyl, phenylcarbonyl, or R₇R₈N-

where R₇ is independently selected from hydrogen, C₁₋₅alkyl,

10 cycloC₁₋₅alkyl, or R₇ is taken together with R₈ to form a 5 or 6 membered heterocyclic ring with one or more heteroatoms selected from the group consisting of oxygen, nitrogen or sulfur and N-oxides thereof;

15 R₈ is independently selected from hydrogen, C₁₋₅alkyl, cycloC₁₋₅alkyl or taken together with R₇ to form a 5 or 6 membered heterocyclic ring with one or more heteroatoms selected from the group consisting of oxygen, nitrogen or sulfur, and N-oxides thereof;

20 R₆ is selected from hydrogen, halogen, C₁₋₅alkoxy, C₁₋₅alkylamino, or di-C₁₋₅alkylamino ;

and the pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein:

25 R₁ is selected from phenylaminocarbonyl, phenylcarbonyl, substituted phenylaminocarbonyl, substituted phenylcarbonyl, and hydrogen;

R₂ is phenylC₁₋₅alkyl;

R₃ is hydrogen;

R₄ is trifluoromethylacetyl;


R₅ is O-(CH₂)₂-morpholin-1-yl;

30 R₆ is hydrogen


n is 0; and

m is 1.


3. The compound according to claim 1 of the formula:




- 5 4. The compound according to claim 1 of the formula:




5. The compound according to claim 1 of the formula:



6. The compound according to claim 1 of the formula:



7. The compound according to claim 1 of the formula:



8. A pharmaceutical composition for treating disorders associated with
25 the motilin receptor comprising an effective amount of a compound of claim 1
in association with one or more pharmaceutically acceptable carriers.

9. A method of treating disorders associated with the motilin receptor in
humans comprising administering to a human in need of such treatment an
30 effective amount of a compound of claim 1.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/22765

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D295/08 C07D295/22 C07C233/41 A61K31/535

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	T.L. PEETERS: OLD HERBORN UNIV. SEMIN. MONOGR., vol. 9, 1997, pages 77-87, XP002096730	1-9
A	CHEMICAL ABSTRACTS, vol. 122, no. 5, 30 January 1995 Columbus, Ohio, US; abstract no. 47011, XP002096731 see abstract & P. POITRAS ET AL.: BIOCHEM. BIOPHYS. RES. COMMUN., vol. 205, no. 1, 1994, pages 449-454, --- -/-	1-9

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search

16 March 1999

Date of mailing of the international search report

01/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 851 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/22765

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 120, no. 17, 25 April 1994 Columbus, Ohio, US; abstract no. 208293, XP002096732 see abstract & T.L. PEETERS ET AL.: BIOVHEM. BIOPHYS. RES. COMMUN., vol. 198, no. 2, 1994, pages 411-416. ---	1-9
A	DATABASE WPI Week 9530 Derwent Publications Ltd., London, GB; AN 95-228692 XP002096734 & JP 07 138284 A (CHUGAI PHARM. CO., LTD.) , 30 May 1995 see abstract ---	1-9
A,P	CHEMICAL ABSTRACTS, vol. 127, no. 24, 15 December 1997 Columbus, Ohio, US; abstract no. 326633, XP002096733 see abstract & MITZUMOTO AKIYOSHI ET AL.: HORMON TO RINSHO, vol. 45, no. 10, 1997, pages 981-988. -----	1-9